CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast CancerXavier Pivot, Semiglazov Vf, Stephen Chan et al.|Journal of Clinical Oncology|2015Cited by 253
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast CancerErika Hamilton, Miguel Martín, Javier Cortés et al.|Clinical Breast Cancer|2020Cited by 42
A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)Petr Krivorotko, Alexey Manikhas, Bogusława Karaszewska et al.|Annals of Oncology|2018Cited by 0